Last reviewed · How we verify
R-MANT
R-MANT is a rituximab-based immunochemotherapy regimen combining rituximab with chemotherapy agents for treatment of lymphoid malignancies.
R-MANT is a rituximab-based immunochemotherapy regimen combining rituximab with chemotherapy agents for treatment of lymphoid malignancies. Used for Lymphoma (specific subtype under investigation in phase 3 trial by Fondazione Italiana Linfomi).
At a glance
| Generic name | R-MANT |
|---|---|
| Also known as | Rituximab (R) |
| Sponsor | Fondazione Italiana Linfomi - ETS |
| Drug class | Monoclonal antibody + chemotherapy combination |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
R-MANT likely refers to a rituximab-containing regimen (possibly rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone or similar CHOP-like backbone) used in lymphoma treatment. Rituximab is a chimeric monoclonal antibody targeting CD20 on B cells, leading to antibody-dependent cellular cytotoxicity and direct apoptosis, combined with cytotoxic chemotherapy for enhanced anti-tumor effect.
Approved indications
- Lymphoma (specific subtype under investigation in phase 3 trial by Fondazione Italiana Linfomi)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Infection
- Nausea/vomiting
- Infusion reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |